Evidence map›Paper›PMID 40354477›Full record

ArticlePloS one2025

The effect of the universal test and treat strategy on the kidney function in adults living with HIV in Zambia: A six-month multicenter cohort study.

Lukundo Siame, Matenge Mutalange, Chitalu Chanda, Morgan Sakala, Chilala Cheelo, Kingsley Kamvuma, Geofrey Mupeta, Martin Chakulya, Memory Ngosa, Michelo Haluuma Miyoba and 3 more

Abstract readMulticenter Study
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lukundo SiameMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.ORCID https://orcid.org/0009-0002-4810-7352
Matenge MutalangeMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Chitalu ChandaMinistry of Health, Lusaka, Zambia.ORCID https://orcid.org/0000-0003-1186-5045
Morgan SakalaMinistry of Health, Choma, Zambia.
Chilala CheeloMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Kingsley KamvumaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Geofrey MupetaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Martin ChakulyaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Memory NgosaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Michelo Haluuma MiyobaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Situmbeko LiweleyaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Sepiso K MasengaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.
Benson M HamooyaMulungushi University School of Medicine and Health Sciences, Livingstone, Zambia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKidney disease is prevalent among people living with HIV (PLHIV), especially in Sub-Saharan Africa (SSA), due to complications of HIV infection, co-morbidities, and antiretroviral therapy (ART). Despite SSA shouldering a disproportionate burden of HIV, there is limited data on the effect of clinical and demographic factors on the kidney with the introduction of the Test and Treat policy. This study aimed to determine the incidence and factors associated with kidney impairment among PLHIV on ART in the Southern Province of Zambia.

methodsWe conducted a retrospective cohort study among 1216 adult individuals living with HIV who initiated ART between January 1, 2014, and July 31, 2016 [before test-and-treat cohort (BTT), n = 814] and August 1, 2016, and October 1, 2020 [after test-and-treat cohort (ATT), n = 402] without kidney function impairment at baseline, followed for 6 months in 12 districts of the Southern Province. The primary outcome was kidney function impairment, defined by an estimated glomerular filtration rate (eGFR) of < 60 ml/min/1.73m² estimated using the Modification of Diet in Renal Disease (MDRD) equation. We used multivariable logistic regression (xtlogit model) to identify factors associated with kidney function impairment. Statistical significance was set at p < 0.05.

resultsThe median age was 36.4 years (interquartile range (IQR): 29.9, 43.3), and the majority of participants were women (57.2%, n = 695). Tenofovir Disoproxil Fumarate (TDF) and XTC exposure was noted among 1,173/1216 (96.5%) enrolled participants and 92.9% (26/28)of those with renal impairment. The overall cumulative incidence of kidney impairment was 2.3% (n = 28/1216: 95% confidence interval (CI) 3%, 5%), and it was higher BTT compared to the ATT (2.8% vs. 1.2%). Every unit increase in age was associated with an increased odds of having kidney function impairment (adjusted odds ratio (AOR):1.05, 95% CI: 1.01-1.09, p = 0.008).. Participants from urban facilities also had a higher risk (AOR: 5.14, 95% CI: 1.95-13.55, p < 0.001). In contrast, being enrolled after the implementation of the "test-and-treat" policy was associated with lower odds of having kidney function impairment (AOR: 0.45, 95% CI: 0.12-0.97, p = 0.042).

conclusionsThis study found a 2.3% incidence of kidney function impairment among PLHIV within 6 months of initiating ART. An increase in age and receiving care at an urban facility were positively associated with kidney function impairment, whereas ART enrollment following the implementation of the "test-and-treat" policy was negatively associated. This study highlights the benefits of early ART initiation on kidney function, reinforcing the need to maintain the universal test-and-treat policy.

Indexed as

Anti-HIV AgentsHIV InfectionsKidneyKidney DiseasesAdultCohort StudiesFemaleGlomerular Filtration RateHumansIncidenceMaleMiddle AgedRetrospective StudiesTenofovirZambiaAnti-HIV AgentsTenofovir

Identifiers

PMID40354477
PMCPMC12068582

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.